The evolving paradigm in the management of intracranial atherosclerotic disease
- PMID: 22220280
- PMCID: PMC3246764
- DOI: 10.1155/2012/289852
The evolving paradigm in the management of intracranial atherosclerotic disease
Abstract
Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke worldwide and represents a significant health problem. The pathogenesis and natural history of ICAD are poorly understood, and rigorous treatment paradigms do not exist as they do for extracranial atherosclerosis. Currently, the best treatment for ICAD remains aspirin therapy, but many patients who are placed on aspirin continue to experience recurrent strokes. As microsurgical and endovascular techniques continue to evolve, the role of extracranial to intracranial bypass operations and stenting are increasingly being reconsidered. We performed a PubMed review of the English literature with a particular focus on treatment options for ICAD and present evidence-based data for the role of surgery and stenting in ICAD against medical therapy alone.
Figures
Similar articles
-
Prevalence, diagnosis and management of intracranial atherosclerosis in White populations: a narrative review.Neurol Res Pract. 2024 Nov 11;6(1):54. doi: 10.1186/s42466-024-00341-4. Neurol Res Pract. 2024. PMID: 39523357 Free PMC article. Review.
-
Submaximal angioplasty for symptomatic intracranial atherosclerosis: a prospective Phase I study.J Neurosurg. 2016 Oct;125(4):964-971. doi: 10.3171/2015.8.JNS15791. Epub 2016 Jan 8. J Neurosurg. 2016. PMID: 26745485 Clinical Trial.
-
Endovascular treatment of symptomatic intracranial atherosclerotic disease.Front Neurol. 2011 Feb 14;1:160. doi: 10.3389/fneur.2010.00160. eCollection 2011. Front Neurol. 2011. PMID: 21359195 Free PMC article.
-
European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease.Eur Stroke J. 2022 Sep;7(3):III-IV. doi: 10.1177/23969873221099715. Epub 2022 Jun 3. Eur Stroke J. 2022. PMID: 36082254 Free PMC article.
-
Consensus conference on intracranial atherosclerotic disease: rationale, methodology, and results.J Neuroimaging. 2009 Oct;19 Suppl 1:1S-10S. doi: 10.1111/j.1552-6569.2009.00414.x. J Neuroimaging. 2009. PMID: 19807850
Cited by
-
Current status and outlook of biodegradable metals in neuroscience and their potential applications as cerebral vascular stent materials.Bioact Mater. 2021 Oct 11;11:140-153. doi: 10.1016/j.bioactmat.2021.09.025. eCollection 2022 May. Bioact Mater. 2021. PMID: 34938919 Free PMC article. Review.
-
Endovascular revascularization for basilar artery occlusion.Interv Neurol. 2015 Jan;3(1):31-40. doi: 10.1159/000368968. Interv Neurol. 2015. PMID: 25999990 Free PMC article. Review.
References
-
- Wong KS, Huang YN, Gao S, Lam WWM, Chan YL, Kay R. Intracranial stenosis in Chinese patients with acute stroke. Neurology. 1998;50(3):812–813. - PubMed
-
- Arenillas JF, Molina CA, Chacón P, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology. 2004;63(1):27–32. - PubMed
-
- Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan stroke study. Stroke. 1995;26(1):14–20. - PubMed
-
- Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine. 2005;352(13):1305–1316. - PubMed
-
- Wong KSL, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. The Lancet Neurology. 2010;9(5):489–497. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials